美国 · SEC FORM 4
Sionna Therapeutics, Inc.
SION · Nasdaq · CIK 0002036042 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
22 同一窗口内观察到的 Form 4 交易行
15 sales · 7 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-06-27 · COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON · $950.4K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Thompson Peter A.Director
▼▼▼▼▼▼
ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCDirector
▼▼▼▼▼▼
Fitzpatrick JenniferCLO and Head of Program Mgmt.
○▼○
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Director; Director,TenPercentOwner
▼
Ridloff ElenaCFO and CBO
○
McKee CharlotteCMO and Head of R&D
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-06-27 · COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON.
近期 Form 4 活动
0买入
108卖出
13其他 Form 4 交易行
35SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出15 sale line(s) · 仅供背景
其他7 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 3,797,732
- 上期报告
- 3,966,138
- 日均成交量
- 1,647,766
- 回补天数
- 2.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-06-27 | COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON | 买入 (P) | Common Stock | 60,000 | USD 15.84 | USD 950,400 | SEC 申报 ↗ |
| 2025-02-10 | COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON | 买入 (P) | Common Stock | 1,125,000 | USD 18.00 | USD 20,250,000 | SEC 申报 ↗ |
| 2025-02-10 | Thompson Peter A. | 买入 (P) | Common Stock | 550,000 | USD 18.00 | USD 9,900,000 | SEC 申报 ↗ |
| 2025-02-10 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 买入 (P) | Common Stock | 550,000 | USD 18.00 | USD 9,900,000 | SEC 申报 ↗ |
| 2025-02-10 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 1,125,000 | USD 18.00 | USD 20,250,000 | SEC 申报 ↗ |
| 2025-02-10 | Booth Bruce | 买入 (P) | Common Stock | 60,000 | USD 18.00 | USD 1,080,000 | SEC 申报 ↗ |
| 2025-02-10 | Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund II, L.P. | 买入 (P) | Common Stock | 60,000 | USD 18.00 | USD 1,080,000 | SEC 申报 ↗ |
Form 4 申报证据
121 transaction lines in the latest 365-day window; 201 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M. | 卖出 (S) | Common Stock | 3,448,811 | USD 6.33 | USD 21,835,018 | SEC 申报 ↗ |
| 2026-09-17 | Ridloff Elena | 奖励／授予 (A) | Common Stock | 94,537 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-17 | McKee Charlotte | 奖励／授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M. | 卖出 (S) | Common Stock | 3,448,811 | USD 6.33 | USD 21,835,018 | SEC 申报 ↗ |
| 2026-09-17 | Ridloff Elena | 奖励／授予 (A) | Common Stock | 94,537 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-17 | McKee Charlotte | 奖励／授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-17 | Fitzpatrick Jennifer | 奖励／授予 (A) | Common Stock | 56,265 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-17 | Cloonan Michael | 奖励／授予 (A) | Common Stock | 109,025 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-07 | Thompson Peter A. | 卖出 (S) | Common Stock | 85,918 | USD 44.86 | USD 3,854,281 | SEC 申报 ↗ |
| 2026-07-07 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 85,918 | USD 44.86 | USD 3,854,281 | SEC 申报 ↗ |
| 2026-07-06 | Fitzpatrick Jennifer | 卖出 (S) | Common Stock | 10,250 | USD 43.60 | USD 446,900 | SEC 申报 ↗ |
| 2026-07-06 | Fitzpatrick Jennifer | 期权行权／转换 (M) | Common Stock | 10,250 | USD 6.11 | USD 62,628 | SEC 申报 ↗ |
| 2026-06-30 | Thompson Peter A. | 卖出 (S) | Common Stock | 115,844 | USD 45.50 | USD 5,270,902 | SEC 申报 ↗ |
| 2026-06-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 115,844 | USD 45.50 | USD 5,270,902 | SEC 申报 ↗ |
| 2026-05-27 | Thompson Peter A. | 卖出 (S) | Common Stock | 101 | USD 44.49 | USD 4,493 | SEC 申报 ↗ |
| 2026-05-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 101 | USD 44.49 | USD 4,493 | SEC 申报 ↗ |
| 2026-05-11 | Thompson Peter A. | 卖出 (S) | Common Stock | 184,639 | USD 46.22 | USD 8,534,015 | SEC 申报 ↗ |
| 2026-05-11 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 184,639 | USD 46.22 | USD 8,534,015 | SEC 申报 ↗ |
| 2026-05-08 | Thompson Peter A. | 卖出 (S) | Common Stock | 59,767 | USD 44.58 | USD 2,664,413 | SEC 申报 ↗ |
| 2026-05-08 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 59,767 | USD 44.58 | USD 2,664,413 | SEC 申报 ↗ |
| 2026-05-07 | Thompson Peter A. | 卖出 (S) | Common Stock | 48,546 | USD 44.61 | USD 2,165,637 | SEC 申报 ↗ |
| 2026-05-07 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 48,546 | USD 44.61 | USD 2,165,637 | SEC 申报 ↗ |
| 2026-04-18 | Thompson Peter A. | 卖出 (S) | Common Stock | 2,948 | USD 44.52 | USD 131,245 | SEC 申报 ↗ |
| 2026-04-18 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 2,948 | USD 44.52 | USD 131,245 | SEC 申报 ↗ |
| 2026-04-17 | Thompson Peter A. | 卖出 (S) | Common Stock | 52,397 | USD 44.68 | USD 2,341,098 | SEC 申报 ↗ |
| 2026-04-17 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 52,397 | USD 44.68 | USD 2,341,098 | SEC 申报 ↗ |
| 2026-04-16 | Thompson Peter A. | 卖出 (S) | Common Stock | 226,906 | USD 45.34 | USD 10,287,918 | SEC 申报 ↗ |
| 2026-04-16 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 226,906 | USD 45.34 | USD 10,287,918 | SEC 申报 ↗ |
| 2026-04-15 | Thompson Peter A. | 卖出 (S) | Common Stock | 235,863 | USD 44.64 | USD 10,528,924 | SEC 申报 ↗ |
| 2026-04-15 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 235,863 | USD 44.64 | USD 10,528,924 | SEC 申报 ↗ |
| 2026-04-14 | Thompson Peter A. | 卖出 (S) | Common Stock | 47,814 | USD 44.51 | USD 2,128,201 | SEC 申报 ↗ |
| 2026-04-14 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | 卖出 (S) | Common Stock | 47,814 | USD 44.51 | USD 2,128,201 | SEC 申报 ↗ |
| 2026-03-05 | Fitzpatrick Jennifer | 卖出 (S) | Common Stock | 10,250 | USD 33.86 | USD 347,065 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SION |
| CIK | 0002036042 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 201 transaction lines from 2025-02-10 to 2026-09-17 8 P purchase lines · 160 S sale lines · 33 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.